10:08 , Apr 30, 2019 |  BioCentury  |  Finance

How Nextech-led round will help Vividion to POC

After identifying three lead programs with its proteome-wide small molecule screening platform, San Diego-based Vividion has raised $82 million in an oversubscribed series B round led by new investor Nextech Invest. Now flush with over...
00:24 , Apr 12, 2019 |  BC Innovations  |  Product Development

NLRP3 early and often

Inflammasome inhibitors could offer a step change for a slew of inflammatory diseases and pharma is taking notice. Two acquisitions in six months show the first inflammasome target -- NLRP3 -- is gaining momentum, but...
16:15 , Oct 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Hematology

INDICATION: Anemia Cell culture and mouse studies suggest inhibiting SH2B3 could help treat FANCD2-deficient Fanconi anemia, a disorder involving loss of hematopoietic stem and progenitor cells (HSPCs). In FANCD2-deficient mouse HSPCs, SH2B3 knockout increased growth...
16:43 , Apr 17, 2018 |  BC Extra  |  Preclinical News

New protein complex sensitizes cancers to PARP inhibitors

Researchers at University of Copenhagen and colleagues used a network-based proteomics approach to identify shieldin, a protein complex that sensitizes BRCA1-deficient cancers to PARP inhibitors, suggesting that shieldin component levels could guide precision medicine strategies....
19:58 , Sep 21, 2017 |  BC Innovations  |  Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
01:10 , May 13, 2017 |  BioCentury  |  Emerging Company Profile

Dialing down dynamin

Dynacure S.A.S. is developing an antisense oligonucleotide against DNM2 that could treat all three subtypes of centronuclear myopathy, two of which are not covered by industry’s pipeline. Centronuclear myopathy (CNM) is a group of rare...
07:00 , Aug 4, 2016 |  BC Innovations  |  Targets & Mechanisms

Cereblon ambition

Most anti-cancer strategies aim to block overactive proteins by directly inhibiting their activity, but a growing number of companies are developing ways to tag the proteins for destruction by recruiting the enzymes that shuttle them...
08:00 , Jan 7, 2016 |  BC Innovations  |  Product R&D

Notorious RBC

  Rubius Therapeutics Inc. emerged from stealth mode last month to announce the first candidate from its engineered red blood cell platform. Behind that program, the company has an arsenal of tailored "red-cell therapeutics" that...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Clinical News

SEQPRO LIPO IS regulatory update

Progenika received CE Mark approval for SEQPRO LIPO IS to diagnose familial hypercholesterolemia ( FH ). The next-generation sequencing test runs on the Illumina MiSeq sequencer and sequences 6 genes associated with FH: low-density lipoprotein...
08:00 , Nov 19, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Suppression of SH2B adaptor protein 3 (SH2B3; LNK) to produce red blood cells (RBCs) from stem cells

Drug platforms TECHNOLOGY: Cell therapy SH2B3 suppression in human hematopoietic stem/progenitor cells (HSPCs) or human embryonic stem cells (hESCs) could be used for in vitro generation of RBCs used in transfusions. In 4,678 healthy subjects...